Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8782143 | 0.98 | HTR2A (0.52) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL9147651 | 0.96 | HTR2A (0.50) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9549516 | 0.96 | HTR2A (0.53) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL190865 | 0.94 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL246032 | 0.92 | HTR2A (0.58) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL28158895 | 0.91 | HTR2A (0.56) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Iodide SCHEMBL4110593 | 0.90 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8861752 | 0.90 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Phosphoric Acid SCHEMBL9549586 | 0.90 | HTR2A (0.47) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 | |
| Acetic Acid SCHEMBL9549692 | 0.87 | ALDH1A1 (0.46) | HTR2AHRH1HIF1ASIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125339-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12459885-B2 | Ionizable cationic lipids | TRANSLATE BIO, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12331005-B2 | Ionizable cationic lipids | TRANSLATE BIO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250162977-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240425442-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240383841-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2024-11-21 | — | — | US | disclosed |
| US-11999675-B2 | Ionizable cationic lipids | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3620447-B1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210009503-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10766852-B2 | Ionizable cationic lipids | TRANSLATE BIO, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-9546128-B2 | Ionizable cationic lipids | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150166462-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2015-06-18 | — | — | US | disclosed |
| EP-2830595-A1 | IONIZABLE CATIONIC LIPIDS | Shire Human Genetic Therapies, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013149140-A1 | IONIZABLE CATIONIC LIPIDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-5677287-A | TREATS MYCOPLASMIC INFECTIONS | PFIZER INC. (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1994021657-A1 | ANTIBACTERIAL 16-MEMBERED RING MACROLIDES CONTAINING OLEFINS AT C-20 | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5208317-A | Molding materials of cured epoxy resins | THE DOW CHEMICAL COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| US-5109099-A | ADVANCING EPOXY RESINS IN PRESENCE OF AMINO GROUP-CONTAINING PHOSPHONIUM CATALYST | THE DOW CHEMICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0441243-A2 | Precatalyzed catalyst compositions, process for preparing epoxy resins, curable compositions, articles resulting from curing the resultant compositions | THE DOW CHEMICAL COMPANY (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4981926-A | Rapid and selective curing using phosphonium catalyst containing an amine group; polyepoxides | THE DOW CHEMICAL COMPANY (US) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766852-B2 | Ionizable cationic lipids | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-12331005-B2 | Ionizable cationic lipids | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-12459885-B2 | Ionizable cationic lipids | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20150166462-A1 | IONIZABLE CATIONIC LIPIDS | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20210009503-A1 | IONIZABLE CATIONIC LIPIDS | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-11999675-B2 | Ionizable cationic lipids | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20240383841-A1 | IONIZABLE CATIONIC LIPIDS | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20250162977-A1 | IONIZABLE CATIONIC LIPIDS | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20240425442-A1 | IONIZABLE CATIONIC LIPIDS | SGMS2, PHOSPHO1, ANXA6 | HTR2A 3925/4885HRH1 2064/4885HIF1A 4394/4885 |
| US-20260125339-A1 | IONIZABLE CATIONIC LIPIDS | NPC1L1, PHOSPHO1, NPC1 | HTR2A 2709/4885HRH1 2537/4885HIF1A 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.